In a clinically improving patient with a white‑blood‑cell count of 30 ×10⁹/L on day 3 of meropenem therapy, should the meropenem be continued and how should the leukocytosis be monitored?

Continue Meropenem and Monitor the Leukocytosis

In a clinically improving patient on day 3 of meropenem with a WBC of 30 ×10⁹/L, continue the current antibacterial therapy without modification. Clinical stability takes precedence over isolated laboratory abnormalities when assessing treatment response 1.

Clinical Decision Framework

Continue Current Therapy

The guideline-based approach is clear: if the patient is clinically stable, continue with initial antibacterial therapy 1. Your patient's clinical improvement is the most important indicator of treatment success, not the WBC count in isolation. The elevated WBC at day 3 does not warrant changing or stopping meropenem when clinical parameters are trending favorably.

Understanding the Leukocytosis

Leukocytosis is a recognized hematologic effect of meropenem and is explicitly listed in the FDA drug label as an adverse reaction 2. This can occur independent of infection status and does not necessarily indicate treatment failure or worsening infection. The key distinction is:

• Clinical improvement = infection is being controlled
• Isolated lab abnormality = may be drug-related or part of the inflammatory response resolution

Monitoring Strategy

Implement daily assessment until resolution 1:

• Daily CBC monitoring to track WBC trend
• Daily clinical assessment of fever, hemodynamics, source control
• Differential count to distinguish between neutrophilia vs other cell lines
• Inflammatory markers (CRP, procalcitonin if available) to correlate with clinical picture

Decision Points at 48 Hours (Day 5 Total)

Re-evaluate the patient systematically:

If patient remains clinically stable AND afebrile:

• Continue meropenem regardless of WBC count
• The WBC elevation alone does not indicate treatment failure

If fever persists beyond day 4-6:

• Consider imaging (chest CT, abdominal CT) to exclude fungal infection or abscesses 1
• Consider adding antifungal therapy 1
• Seek infectious disease consultation 1

If clinical deterioration occurs:

• Broaden antibacterial coverage or rotate therapy 1
• Add glycopeptide coverage 1
• Urgent ID consultation 1

Important Caveats

Drug-Induced Leukocytosis

Meropenem can cause both leukocytosis and leukopenia 2. At therapeutic concentrations (5-20 mcg/mL), meropenem does not substantially modify leukocyte function 3, so the elevated count is likely reactive rather than functional impairment.

Renal Function Monitoring

Ensure daily renal function assessment 1. Meropenem requires dose adjustment if creatinine clearance drops below 50 mL/min 2. Accumulation in renal impairment increases risk of seizures and other adverse effects.

Do Not Stop Prematurely

Do not discontinue meropenem based solely on WBC count. Duration of therapy should be guided by 1:

• Clinical resolution (afebrile for 48 hours)
• Source control achieved
• Negative blood cultures
• Typically 5-7 days minimum for serious infections

What This Is NOT

This isolated leukocytosis on day 3 with clinical improvement is not:

• An indication to stop meropenem
• An indication to add additional antibiotics
• An indication for immediate imaging (unless fever persists or clinical deterioration)
• A sign of treatment failure

The clinical trajectory trumps the laboratory value in this scenario 1.